Icagen to continue Assert trial testing ICA-17043

By Elaine Rigoli

Tampa, Fla., Sept. 12 - Icagen, Inc. said Tuesday that, following a recent meeting of the independent data monitoring committee of the company's phase 3 clinical trial for the treatment of sickle cell disease, the committee recommended that the Assert trial continue its enrollment of patients on concurrent hydroxyurea therapy.

This second meeting followed a review of an updated data set as requested by the committee at a meeting earlier this year.

The company said it will meet with the Food and Drug Administration soon to discuss the implications of the committee's recommendations on its plans for clinical trials of ICA-17043.

Icagen is a biopharmaceutical company based in Research Triangle Park, N.C.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.